Hepatoma Research

Scope & Guideline

Advancing the Frontiers of Liver Cancer Research

Introduction

Delve into the academic richness of Hepatoma Research with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2394-5079
PublisherOAE PUBLISHING INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2019 to 2024
AbbreviationHEPATOMA RES / Hepatoma Res.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address245 E MAIN ST, ST122, ALHAMBRA, CA 91801

Aims and Scopes

Hepatoma Research is dedicated to advancing the understanding and treatment of liver cancers, particularly hepatocellular carcinoma (HCC) and cholangiocarcinoma. The journal emphasizes innovative research methodologies that span clinical, translational, and basic science, aiming to improve patient outcomes and treatment modalities.
  1. Hepatocellular Carcinoma (HCC) Research:
    The journal focuses extensively on various aspects of HCC, including its risk factors, molecular mechanisms, treatment strategies, and outcomes, thereby contributing to a better understanding of this prevalent liver cancer.
  2. Cholangiocarcinoma Studies:
    Cholangiocarcinoma, another critical area of focus, is explored through studies that cover its epidemiology, molecular pathology, and treatment advancements, highlighting the need for improved management strategies.
  3. Innovative Treatment Modalities:
    There is a consistent emphasis on novel treatment approaches, including minimally invasive surgeries, radiation therapies, and the use of immunotherapy and targeted therapies, reflecting the journal's commitment to advancing clinical practice.
  4. Multidisciplinary Approaches:
    The journal promotes multidisciplinary research and treatment approaches, integrating perspectives from surgery, oncology, radiology, and pathology to provide comprehensive care for liver cancer patients.
  5. Patient-Centric Research:
    Hepatoma Research also prioritizes research that addresses patient perspectives, quality of life, and real-world outcomes, fostering a holistic understanding of treatment impacts.
The journal has shown a dynamic evolution in its research focus, with several emerging themes gaining significant attention in recent publications. These trends reflect the ongoing advancements in understanding liver cancer and the pursuit of innovative treatment strategies.
  1. Immunotherapy and Checkpoint Inhibitors:
    Recent publications highlight the growing interest in immunotherapy, particularly immune checkpoint inhibitors, as promising treatment options for HCC, reflecting a shift towards harnessing the immune system in cancer treatment.
  2. Minimally Invasive Surgical Techniques:
    There is an increasing trend in research dedicated to minimally invasive surgical techniques for liver cancer treatment, indicating a broader acceptance and application of these approaches in clinical practice.
  3. Molecular and Genetic Profiling:
    Emerging studies focus on the molecular and genetic profiling of liver cancers, which is crucial for the development of personalized medicine strategies and targeted therapies.
  4. Microbiome and Liver Health:
    Recent articles explore the relationship between the gut microbiome and liver diseases, signaling an emerging interest in how microbial health impacts liver cancer development and progression.
  5. Real-World Data and Patient Outcomes:
    An emphasis on real-world data analysis and patient outcomes has emerged, reflecting a growing interest in understanding the effectiveness and impact of treatments in diverse populations.

Declining or Waning

As the field of liver cancer research evolves, certain themes appear to be diminishing in prominence within the journal's recent publications. These waning scopes may reflect shifts in research priorities or advancements in understanding that render previous approaches less relevant.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decline in papers focusing on conventional chemotherapy regimens for liver cancer, as newer targeted therapies and immunotherapies gain traction and demonstrate better efficacy.
  2. Basic Science without Clinical Application:
    Research that solely delves into basic science without a clear translational application seems to be less prominent, indicating a shift towards studies that emphasize clinical relevance and applicability in patient care.
  3. Liver Cancer Surveillance Protocols:
    While surveillance remains crucial, the frequency of studies focused on traditional surveillance protocols has decreased, possibly due to increased emphasis on personalized and risk-based screening strategies.

Similar Journals

World Journal of Clinical Oncology

Illuminating the Path to Oncology Excellence
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

Clinical Lung Cancer

Empowering clinicians with cutting-edge lung cancer studies.
Publisher: CIG MEDIA GROUP, LPISSN: 1525-7304Frequency: 6 issues/year

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

Surgical Oncology Clinics of North America

Your Gateway to Surgical Oncology Expertise
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 1055-3207Frequency: 4 issues/year

Surgical Oncology Clinics of North America, published by W B Saunders Co-Elsevier Inc, is a leading journal in the fields of surgical oncology and surgery, captivating readers since its inception in 1995. With ISSN 1055-3207 and E-ISSN 1558-5042, this esteemed journal offers a comprehensive platform for the dissemination of cutting-edge research, clinical studies, and expert reviews pertaining to surgical techniques and oncological advancements. The journal currently holds a commendable Q3 ranking in Oncology and a Q2 ranking in Surgery, underpinned by its impressive Scopus rankings that place it in the top 25% of its category in Medicine, particularly in the surgical domain (Rank #137/551). Although it does not operate under an open-access model, the insights shared within its pages are invaluable for researchers, healthcare professionals, and students dedicated to enhancing patient outcomes in surgical oncology. With a commitment to advancing medical knowledge, Surgical Oncology Clinics of North America remains a crucial resource for those pursuing excellence in surgical practices and oncology treatment methodologies.

Liver Cancer

Leading the way in liver cancer research and discovery.
Publisher: KARGERISSN: 2235-1795Frequency: 6 issues/year

Liver Cancer is a premier, peer-reviewed journal dedicated to the comprehensive study and advancement of knowledge surrounding liver neoplasms. Published by KARGER and headquartered in Switzerland, this journal has been an open-access platform since 2012, providing researchers with invaluable insights into the rapidly evolving field of hepatology and oncology. With an impressive impact factor that places it in the Q1 category for both Hepatology and Oncology in 2023, Liver Cancer stands out as a high-impact conduit for groundbreaking research, ranking #19 out of 404 in Medicine _ Oncology and #6 out of 82 in Medicine _ Hepatology according to Scopus. Researchers, practitioners, and students are encouraged to engage with the journal's content, which encompasses clinical studies, basic research, and reviews that contribute significantly to understanding liver cancer dynamics, diagnosis, and treatment strategies. This journal not only facilitates the dissemination of knowledge but also fosters collaboration in a well-established and impactful global scientific community.

Current Problems in Cancer: Case Reports

Illuminating the complexities of cancer, one case at a time.
Publisher: ELSEVIERISSN: 2666-6219Frequency: 2 issues/year

Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.

Clinical and Molecular Hepatology

Advancing liver health through innovative research.
Publisher: KOREAN ASSOC STUDY LIVERISSN: 2287-2728Frequency: 4 issues/year

Clinical and Molecular Hepatology, published by the Korean Association for the Study of Liver, stands at the forefront of hepatology, offering a significant platform for research and innovation in liver diseases. Established in 1995 as an open access journal, it aims to disseminate high-quality research that spans the fields of hepatology, molecular biology, and medicine. With an impressive impact factor ranking it in the Q1 category for 2023 in both Hepatology and Molecular Biology, the journal facilitates a rich exchange of knowledge among professionals, researchers, and students globally. With its dedicated coverage from 2012 to 2024 and exceptional Scopus rankings placing it within the top 10% of journals in its field, Clinical and Molecular Hepatology is an indispensable resource for advancing the understanding and treatment of liver conditions. Located in Seoul, South Korea, the journal emphasizes rigorous peer review and is committed to enhancing clinical practice and molecular research, making it an ideal venue for groundbreaking studies in liver health.

Targeted Oncology

Pioneering the path to targeted cancer therapies.
Publisher: SPRINGERISSN: 1776-2596Frequency: 6 issues/year

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.

Clinical Lymphoma Myeloma & Leukemia

Exploring Innovations in Blood Cancer Treatment
Publisher: CIG MEDIA GROUP, LPISSN: 2152-2650Frequency: 6 issues/year

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

Radiation Oncology

Elevating oncology knowledge for better patient outcomes.
Publisher: BMCISSN: Frequency: 1 issue/year

Radiation Oncology is a premier scholarly journal published by BMC, dedicated to advancing the field of oncology through innovative research and comprehensive reviews since its inception in 2005. With its Open Access model, the journal ensures that the latest findings in radiotherapy and cancer treatment are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and healthcare professionals. The journal has garnered an impressive reputation with prestigious rankings, achieving Q1 status in Radiology, Nuclear Medicine and Imaging and Q2 in Oncology as of 2023, reflecting its significant impact on the scientific community. In the Scopus rankings, it stands proud at Rank #61 in Radiology, Nuclear Medicine and Imaging, placing it in the top 81st percentile, and Rank #112 in Oncology at the 72nd percentile. With a converged publication plan extending through 2024, Radiation Oncology remains a vital resource for those dedicated to enhancing cancer treatment methodologies and outcomes.

Oncologie

Exploring innovative solutions in oncology.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.